Loading clinical trials...
Loading clinical trials...
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
Conditions
Interventions
ST-920
Locations
18
United States
University of California, Irvine
Irvine, California, United States
University of South Florida
Tampa, Florida, United States
Emory University School of Medicine
Atlanta, Georgia, United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
University of Iowa Hospital and Clinics
Iowa City, Iowa, United States
University of Minnesota Medical Center
Minneapolis, Minnesota, United States
Start Date
July 23, 2019
Primary Completion Date
April 10, 2025
Completion Date
April 10, 2025
Last Updated
May 15, 2025
NCT07382128
NCT05923788
NCT07277361
NCT04252066
NCT06226987
NCT06065852
Lead Sponsor
Sangamo Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions